The Microarray Shared Resource was created in 1999 to support Mayo Cancer Center Investigators needs for global transcriptional profiling. The major services provided include gene-expression profiling using Affymetrix GeneChips, and verification of expression levels by real-time PCR methods, and quality assessment procedures for RNA. Data analysis has been added as a service in 2003. Services available on a custom basis include custom spotting of oligonucleotide and cDNA microarrays, and hybridization and analysis of BAC assays. Since 2000, the Microarray Shared Resource has supported experiments from over 50 MCCC Investigators. In 2002, investigators from 6 Cancer Center Programs utilized this Shared Resource. Greatest usage in 2002 and 2003 has been from members of the Prostate Cancer and Hematologic Malignancies Programs. The goals for the Microarray Shared Resource are to bring state-of the art improvements in genomics approaches to research in oncology. This includes: i. increasing the sensitivity and specificity of gene-expression profiling experiments by routinely using laser-captured micro-dissected tissues; ii. assessing feasibility of utilizing paraffin-embedded materials; iii. improving the sensitivity of transcriptional profiling for low copy-number transcripts using oligonucleotide microarrays; iv. analysis of small chromosome regions with custom-fabricated BAC microarrays; v. expanding data analysis capacity and sophistication.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-34
Application #
7618236
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
34
Fiscal Year
2008
Total Cost
$240,087
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153

Showing the most recent 10 out of 1129 publications